224 related articles for article (PubMed ID: 18569275)
1. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
Balato A; La Bella S; Gaudiello F; Balato N
J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275
[TBL] [Abstract][Full Text] [Related]
2. Case reports: practical experience with efalizumab in hand and foot psoriasis.
Cohen DJ; Scherschun L
J Drugs Dermatol; 2007 Dec; 6(12):1224-30. PubMed ID: 18189064
[TBL] [Abstract][Full Text] [Related]
3. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.
Berends MA; Driessen RJ; Langewouters AM; Boezeman JB; Van De Kerkhof PC; De Jong EM
J Dermatolog Treat; 2007; 18(2):76-83. PubMed ID: 17520463
[TBL] [Abstract][Full Text] [Related]
4. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
5. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
Ortonne JP; Shear N; Shumack S; Henninger E;
BMC Dermatol; 2005 Dec; 5():13. PubMed ID: 16359548
[TBL] [Abstract][Full Text] [Related]
6. Efalizumab, a reversible T-cell modulator for psoriasis.
Shear NH; Langley RG; Ho V
J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
[TBL] [Abstract][Full Text] [Related]
7. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
8. New-onset, debilitating arthritis in psoriasis patients receiving efalizumab.
Myers WA; Najarian D; Gottlieb AB
J Dermatolog Treat; 2006; 17(6):353-4. PubMed ID: 17853308
[TBL] [Abstract][Full Text] [Related]
9. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB; Gordon KB; Lebwohl MG; Caro I; Walicke PA; Li N; Leonardi CL;
J Drugs Dermatol; 2004; 3(6):614-24. PubMed ID: 15624744
[TBL] [Abstract][Full Text] [Related]
10. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
Papp KA; Miller B; Gordon KB; Caro I; Kwon P; Compton PG; Leonardi CL;
J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
[TBL] [Abstract][Full Text] [Related]
11. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis.
Viguier M; Richette P; Aubin F; Beylot-Barry M; Lahfa M; Bedane C; Delesalle F; Richard-Lallemand MA; Delaporte E; Dubertret L; Bardin T; Bachelez H
Arthritis Rheum; 2008 Jun; 58(6):1796-802. PubMed ID: 18512820
[TBL] [Abstract][Full Text] [Related]
12. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis.
Leonardi C; Menter A; Hamilton T; Caro I; Xing B; Gottlieb AB
Br J Dermatol; 2008 May; 158(5):1107-16. PubMed ID: 18373710
[TBL] [Abstract][Full Text] [Related]
13. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.
Cather JC; Cather JC; Menter A
Expert Opin Biol Ther; 2003 Apr; 3(2):361-70. PubMed ID: 12662148
[TBL] [Abstract][Full Text] [Related]
14. Efalizumab therapy for psoriasis in patients with inadequate responses to etanercept.
Kramer JM; Turner JE
Am J Clin Dermatol; 2009; 10(2):134-40. PubMed ID: 19222255
[TBL] [Abstract][Full Text] [Related]
15. Relapse, rebound, and psoriasis adverse events: an advisory group report.
Carey W; Glazer S; Gottlieb AB; Lebwohl M; Leonardi C; Menter A; Papp K; Rundle AC; Toth D
J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S171-81. PubMed ID: 16488339
[TBL] [Abstract][Full Text] [Related]
16. Efalizumab: new drug. Plaque psoriasis: too many unknowns.
Prescrire Int; 2006 Feb; 15(81):8-11. PubMed ID: 16548097
[TBL] [Abstract][Full Text] [Related]
17. [Efalizumab].
Descamps V
Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):666-78. PubMed ID: 17053736
[TBL] [Abstract][Full Text] [Related]
18. The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.
Bonnekoh B; Böckelmann R; Pommer AJ; Malykh Y; Philipsen L; Gollnick H
Skin Pharmacol Physiol; 2007; 20(2):96-111. PubMed ID: 17167274
[TBL] [Abstract][Full Text] [Related]
19. Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis.
Frampton JE; Plosker GL
Am J Clin Dermatol; 2009; 10(1):51-72. PubMed ID: 19170413
[TBL] [Abstract][Full Text] [Related]
20. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.
Papp KA; Ho V; Langley R; Lynde C; Poulin Y; Shear N; Toole J; Zip C
J Cutan Med Surg; 2006; 9 Suppl 1():26-32. PubMed ID: 16633859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
